Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, the Department of Epidemiology, Harvard School of Public Health, and the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Corresponding author: Rishi J. Desai, MS, PhD, Postdoctoral Research Fellow, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030-R, Boston, MA 02120; e-mail: [email protected].
Supported by Agency for Healthcare Research & Quality Award R01 HSO18533. Brian T. Bateman received additional funding through a K-award (K08HD075831) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health, and Krista F. Huybrechts received additional funding through a K-award (K01 MH099141) from the National Institute of Mental Health.
The authors thank Helen Mogun, MS (Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, Massachusetts) for preparing the analytic data set.
Financial Disclosure Dr. Hernandez-Diaz has consulted for Novartis, AstraZeneca, and GSK_biologics for unrelated projects. Dr. Bateman is supported through a K-award (K08HD075831 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The other authors did not report any potential conflicts of interest.